Search for: "Mylan Pharmaceuticals" Results 281 - 300 of 739
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Feb 2016, 10:43 am by Lawrence B. Ebert
The CAFC affirmed SDNY in the oxycontin case:For the foregoing reasons, we affirm the district court’s invalidity determinations as to the low-ABUK patents and the ’383 patent and the district court’s dis-missal of the Epic, Mylan, and Amneal actions. [read post]
1 Jan 2016, 9:00 am by Dennis Crouch
., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
1 Dec 2015, 6:20 am
”) to ward off an unsolicited takeover bid by the Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd. [read post]
9 Nov 2015, 7:39 am
Merck Sharp & Dohme v Ono Pharmaceutical [2015] EWHC 2973 (Pat), decided on 22 October by Mr Justice Birss in the Patents Court, England and Wales, is a decidedly unbifurcated ruling, being a full-blooded infringement-and-invalidity action running to 243 paragraphs. [read post]
6 Nov 2015, 6:58 am
 Mylan and Actavis were seeking revocation of the patent. [read post]
28 Oct 2015, 5:17 am by Amy Howe
” In a second post at Dubitante, Sadowsky discusses the petition in “an important prescription drug patent case involving similar issues, Mylan Pharmaceuticals vs. [read post]
16 Oct 2015, 8:00 pm by John Ehrett
The petition of the day is: Mylan Pharmaceuticals Inc. v. [read post]
26 Aug 2015, 11:02 am by Lawrence B. Ebert
., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. [read post]
22 Jul 2015, 12:40 pm
Indianapolis, Indiana - An Indiana patent attorney for Eli Lilly and Company of Indianapolis, Indiana sued in the Southern District of Indiana alleging that Mylan Laboratories Limited of Hyderabad, India; Mylan Pharmaceuticals Inc. of Morgantown, West Virginia; and Mylan Inc. of Canonsburg, Pennsylvania (collectively, "Mylan") infringed Patent No. 7,772,209 ("the 209 patent"), which covers the pharmaceutical product… [read post]
3 Jun 2015, 9:55 am by Jennifer Driscoll and Helen C. Eckert
  In December 2002, when generic manufacturers Teva, Ranbaxy, Mylan and Barr sought permission from the FDA pursuant to the Hatch-Waxman Act to market a generic version of Provigil, Cephalon sued the four companies for patent infringement. [read post]
22 May 2015, 10:38 am
Shortly afterwards, the injunction on Krka was lifted.The declaration of non-infringement awarded to Ranbaxy opened the door to the marketing of generic esomeprazole products by a series of other companies, including Arrow, Mylan and Teva. [read post]
14 May 2015, 4:00 am by Paula Bremner
Mylan Pharmaceuticals ULC, 2015 FC 17[7] [tadalafil Notice of Compliance case (“NOC”)], Justice de Montigny accepted that Eli Lilly’s patent for the new use of a drug to treat erectile dysfunction (“ED”) only promised ED treatment. [read post]
14 Apr 2015, 8:34 pm by Aaron Barkoff
The Federal Circuit found that Apotex has a concrete, potentially high-value stake in obtaining a declaratory judgment, and that both Daiichi and generic manufacturer Mylan Pharmaceuticals, Inc. have a concrete, potentially high-value stake in denying Apotex that judgment and thereby delaying Apotex’s market entry. [read post]